Articles By Jack Cush, MD
Lack of Gender Equity in Academic Rheumatology
Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity. To address this, EULAR designed a study using web-based surveys to collect information; here are the results.
Read Article
Excessive Alcohol-Related Deaths in US Adults
Alcohol consumption is a leading preventable cause of death in the U.S. A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49.
Read Article
EMA Crack Down on JAK Inhibitors
The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.
Read Article
From the Archives: Rheumatology Dead Word Cemetery
I recently heard of a secondary school assignment wherein students were challenged to “bury” a word that was no longer useful or appropriate. Their exercise has now evolved into an unofficial RheumNow task force to retire diagnostic terms that have grown into misuse in rheumatology and medicine. How did we decide which words should perish? And by what criteria? Who has the final say?
Read Article
Infections & Lupus (10.28.2022)
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Read Article
Infection: a Leading Cause of Death in Lupus
Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.
Read Article
Increasing Prevalence of RA, PsA and AS in the UK
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.
Read Article
Increasing Risk of Lupus Nephritis
Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.
Read Article
2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis
Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).
Read Article
FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis
On Friday October 21st the U.S. Food and Drug Administration approved upadacitinib (Rinvoq) for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.
Read Article
